Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers?

Respiratory Research

Letter to the Editor

Thierry J. Van Hees¹  Monique A. Henket²  Florence N. Schleich²  Virginie A. Paulus²  Renaud E. Louis²  Sophie F. Demarche³ 

[1] Department of Clinical Pharmacy, Center for Interdisciplinary Research on Medicines, University of Liege, Liege, Belgium;Department of Respiratory Medicine, CHU Liege, GIGA I3 Research Group, University of Liege, Liege, Belgium;Department of Respiratory Medicine, CHU Liege, GIGA I3 Research Group, University of Liege, Liege, Belgium;Department of Clinical Pharmacy, Center for Interdisciplinary Research on Medicines, University of Liege, Liege, Belgium;

关键词: Asthma;    Phenotype;    Biomarkers;    Sputum;    Blood;    Eosinophils;    Nitric oxide;    Immunoglobulin E;   

DOI  :  10.1186/s12931-017-0615-9

 received in 2017-05-04, accepted in 2017-06-25,  发布年份 2017

来源: Springer

【 摘 要 】

The concept of asthma inflammatory phenotypes has proved to be important in predicting response to inhaled corticosteroids. Induced sputum, which has been pivotal in the development of the concept of inflammatory phenotypes, is however not widely available. Several studies have proposed to use surrogate exhaled or blood biomarkers, like fractional exhaled nitric oxide (FENO), blood eosinophils and total serum immunoglobulin E (IgE). However, taken alone, each of these biomarkers has moderate accuracy to identify sputum eosinophilia. Here, we propose a new approach based on the likelihood ratio to study which thresholds of these biomarkers, taken alone or in combination, were able to rule in or rule out sputum eosinophils ≥3%. We showed in a large population of 869 asthmatics that combining FENO, blood eosinophils and total serum IgE could accurately predict sputum eosinophils ≥ or <3% in 58% of our population.

【 授权许可】

CC BY   
© The Author(s). 2017